On September 16, WilmerHale client Palomar Medical Technologies, Inc., a leading researcher and developer of light-based systems for aesthetic treatments, and Syneron Medical Ltd., the leading global aesthetic device company, entered into a comprehensive settlement agreement ending the patent disputes between the companies in which WilmerHale had been representing Palomar and its co-plaintiff, The General Hospital Corporation, which operates Massachusetts General Hospital (MGH). The comprehensive settlement agreement includes two Non-Exclusive Patent License Agreements by Palomar with Candela Corporation (acquired by Syneron in January 2010) and Syneron.
Under the first agreement, Candela and Syneron agreed to pay Palomar $31 million in exchange for a non-exclusive, worldwide, fully paid-up, irrevocable license to US Patent Nos. 5,735,844 and 5,595,568 and foreign counterparts for their professional laser- and lamp-based hair removal systems. In addition, Palomar will receive a royalty-free license to certain Candela patents.
Under the second agreement, Palomar will grant to Syneron and affiliates a non-exclusive, royalty-bearing license in the United States to US Patent Nos. 5,735,844 and 5,595,568 for consumer home-use, lamp-based hair removal products. In addition, Palomar will receive a royalty-free license to certain Syneron and Candela patents. Full details are available here.
This settlement is just one in a series of victories we have obtained for Palomar. Since 1999, WilmerHale has represented Palomar and MGH in a number of disputes involving these patents. This representation has led to more than $125 million in licensing revenue for Palomar and MGH.
WilmerHale Partner Wayne Stoner was lead counsel on all matters for Palomar. His team included Partner Vinita Ferrera; Counsel Kate Saxton and Chris Noyes; Senior Associates Dimple Chaudhary and Sarah Petty; and Associate Leslie Stierman.